Publications by authors named "Veronique Allaria-Lapierre"
Introduction: Long-term glucocorticoid therapy is the leading cause of secondary osteoporosis. The management of glucocorticoid-induced osteoporosis (GIOP) seems to be inadequate in many European countries.
Objective: To evaluate the rate of screening and treatment of GIOP.
Article Synopsis
- The study investigates the extent and patterns of methylphenidate (MPH) abuse, particularly in cases where it is intravenously administered after being crushed.
- Data collected revealed a 166% increase in MPH prescriptions from 2005 to 2011, primarily among male adults with drug dependence, particularly those on opiate treatments.
- The findings highlight significant health risks associated with MPH abuse, such as cardiovascular issues and psychiatric problems, prompting a call for increased awareness and intervention efforts among healthcare professionals.
Introduction: The objective of this study was to estimate and to characterize the actual patterns of triptan use and overuse in France using a drug reimbursement database.
Methods: We included all people covered by the French General Health Insurance System (GHIS) from the Provence-Alpes-Côte-d'Azur (PACA) and Corsica administrative areas who had at least one dispensed dose of triptans between May 2010 and December 2011. All dispensed doses of triptans, migraine prophylactic treatment and psychotropic medications were extracted from the GHIS database.
Aim: The aim of the study was to identify and to characterize patients with Alzheimer's disease or related dementia describing antipsychotics and other psychotropic expositions.
Methods: The study was performed, in 2010, based on Provence-Alpes-Côte d'Azur region (PACA)-Corse Alz cohort included patients with dementia, with chronic condition 'Alzheimer disease or related disease' and/or had at least one delivery of Alzheimer's specific treatment, registered in the General Health Care System. Psychotropic drugs were extracted according anatomical, therapeutical and chemical code.
Objective: To assess the national market penetration rate (PR) of generic high-dosage buprenorphine (HDB) in 2008 and its evolution since their marketing (2006), and making a point for each dosage and at regional level.
Methods: Retrospective study over data using national and regional health reimbursement database over three years (2006-2008).
Results: In 2008, the generic HDB's national MPR was 31%.